Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NUVB | Class A Common Stock | Other | $0 | -368K | -0.63% | $0.00 | 58.3M | Mar 2, 2021 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NUVB | Stock Option (Right to Buy) | Award | $0 | +2.5M | $0.00 | 2.5M | Feb 28, 2023 | Class A Common Stock | 2.5M | $1.94 | Direct | F3 |
Id | Content |
---|---|
F1 | On March 2, 2021, the Reporting Person surrendered 368,408 shares of the Issuer's Class A Common Stock in connection with the satisfaction of the Issuer's obligations to GiraFpharma LLC. |
F2 | Includes 2,661 shares acquired on May 19, 2022 and 1 share acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan. |
F3 | Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date. |